secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001193125-25-276140
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atossa advances (Z)-endoxifen regulatory path; Q3 op-ex $9.3M
-------------------------------------------------------------

- FDA Type C meeting set Nov 17 to discuss accelerated NDA path for (Z)-endoxifen in breast cancer risk reduction; written comments received.
- Appointed Janet R. Rea as SVP R&D and Mark Daniel as CFO to lead commercialization readiness.
- Selected PSI as CRO for planned Phase 2 mBC dose-ranging study; IND filing targeted Q4 2025, topline data in 2026.
- Q3 operating expenses $9.3M (up from $6.4M); interest income $0.6M; net loss not separately disclosed.
- New Israel patent issued; two US patents under post-grant challenges; majority of IP portfolio unaffected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000119312525276140/0001193125-25-276140-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000119312525276140/atos-20251112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-276140

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer